Zapa Jj s.r.o.

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• COPD7 trials
• Asthma4 trials

Phase

• Phase 36 trials
• Phase 24 trials
• Phase 41 trial

Status

• Completed6 trials
• Active, not recruiting4 trials
• Not yet recruiting1 trial

Lead sponsor

• AstraZeneca5 trials
• Sanofi3 trials
• Chiesi Farmaceutici S.p.A.1 trial
• UCB Biopharma SRL1 trial
• Upstream Bio Inc.1 trial

Running trials

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

  NCT07725939· Phase 2· UCB Biopharma SRL· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

  NCT06981078· Phase 2· Upstream Bio Inc.· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

  NCT05097287· Phase 4· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting

Closed trials

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

  NCT06208306· Phase 3· Sanofi· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· AstraZeneca· Source

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04701983· Phase 3· Sanofi· Source